Lance Sloan, MD
Endocrinology, Diabetes & Metabolism · Lufkin, TXNPI 1588665228
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,296,372 of the $1,742,302 with a category attached, or 74.4%. 60 manufacturers reported payments, led by AstraZeneca at 29.8% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,736 payments — averaging $636.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$520K
- Lilly USA, LLC$367K
- Corcept Therapeutics$192K
- Boehringer Ingelheim$189K
- Johnson & Johnson$134K
- Pfizer$54K
- plus $286K from 54 others
Across 304 payments — averaging $6414.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$560K
- Boehringer Ingelheim International GmbH$515K
- Eli Lilly$249K
- Amgen$194K
- GSK$142K
- Boehringer Ingelheim$77K
- plus $213K from 8 others
What the payments were for
- Consulting fees$171,90210%
- Speaking & faculty fees$1,296,37274%
- Travel & lodging$208,72812%
- Food & beverage$65,0554%
- Education$2450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$505,633
- JARDIANCE$440,782
- Korlym$188,319
- INVOKANA$123,213
- ZEPBOUND$81,354
- STEGLATRO$42,425
- PREVNAR 20$40,393
- Kerendia$26,770
- TZIELD$15,453
- TRIFERIC$11,565
- TOUJEO$7,568
- FreeStyle Libre 2$5,095
- LANTUS$4,250
- Tryvio$4,168
- BYDUREON$4,000
- REZDIFFRA$3,887
- FreeStyle Libre Pro$3,375
- FreeStyle Libre$3,150
- Ozempic$2,863
- PREVNAR - 13$2,000
How this compares
$1,742,302 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 626 | $787,102 |
| MounjaroTirzepatide | 395 | $434,398 |
| RecorlevLevoketoconazole | 12 | $338,504 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 331 | $297,730 |
| JardianceEmpagliflozin | 224 | $238,449 |
| Xigduo XrDapaglifloz Propaned/Metformin | 216 | $184,614 |
| FarxigaDapagliflozin Propanediol | 212 | $183,459 |
| TrulicityDulaglutide | 113 | $117,163 |
| Tresiba Flextouch U-200Insulin Degludec | 131 | $110,961 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $103,776 |
| KerendiaFinerenone | 86 | $82,286 |
| NexlizetBempedoic Acid/Ezetimibe | 70 | $46,743 |
| ProliaDenosumab | 27 | $46,619 |
| XphozahTenapanor Hcl | 15 | $42,391 |
| RybelsusSemaglutide | 32 | $41,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba, Fiasp | $28,090 | $854,012692 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $366,697 | $578,685552 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Tradjenta | $188,648 | $570,192598 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $783 | $338,50412 claims |
| AstraZenecaFarxiga | $519,645 | $183,459212 claims |
| BayerKerendia | $33,401 | $82,28686 claims |
| Esperion Therapeutics, Inc.Nexlizet | $202 | $46,74370 claims |
| AmgenProlia | $2,212 | $46,61927 claims |
| AbbVieSynthroid | $121 | $7,026108 claims |
| Sanofi-aventis U.S. LLCLantus | $28,328 | $5,35416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Lufkin
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
- Andres SplenserHouston$923K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.